Key facts
- Micrima’s last known valuation is $8.3M.
- It has raised $23.5M; the latest was Equity Crowdfunding ($1.9M) in Jul 2025.
- Notable investors include Innovate UK, British Business Bank, ACF Investors, Nesta, University of Bristol — 22 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 22 names
- ·Watchlist + deal alerts for Micrima
- ·The full record, as it builds
Funding rounds
No funding rounds for Micrima are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Micrima
Developer of a radio-wave radar imaging technology designed to diagnose breast cancer. The company's breast tissue analysis technology uses harmless radio waves to capture high-resolution, three-dimensional images without the requirement of any breast compression to access personalized imaging approaches and immediate risk awareness, enabling women to get access to a painless and more comfortable alternative for routine breast cancer screening.
- Sector
- Healthcare
- HQ
- Bristol, United Kingdom
- Founded
- 2005
- Employees
- 30
- Website
- micrima.com/
- Ownership
- Privately Held (backing)
Micrima doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Micrima shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Micrima in its N-PORT filings yet. We sweep new filings monthly.